Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Regulation of Food Intake

Regulation of Food Intake

Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Cognitive Bioprediction and Moral Responsibility: Foreseeability, Control and the Ethics of Anticipated Cognitive Impairment.

AJOB neuroscience·2026

Same author

Stability of Transgender Identity in Adolescents Seen in Multidisciplinary Specialized Gender Centers: A Multicenter Study in Canada.

The Journal of adolescent health : official publication of the Society for Adolescent Medicine·2026

Same author

Advancing toward Universal Newborn Screening for Congenital Adrenal Hyperplasia in Indonesia: A Nationwide Study on the Knowledge, Perspectives, and Experience of Pediatric Residents and Pediatricians.

Hormone research in paediatrics·2026

Same author

Comparison of demographics and treatment outcome in children with type 1 diabetes related to the economic background of their country of residence: observations from the SWEET database.

Diabetes research and clinical practice·2025

Same author

Post-Transplant Metabolic Syndrome in Pediatric Liver Transplant Recipients: Definition, Prevalence and Clinical Presentation.

Pediatric transplantation·2025

Same author

Post-Transplant Metabolic Syndrome in Pediatric Liver Transplant Recipients-Contributors, Screening, and Management.

Pediatric transplantation·2025

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

Roux-en-Y Gastric Bypass Operation in Rats

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

Long-acting octreotide treatment causes a sustained decrease in ghrelin concentrations but does not affect weight,

Kathleen De Waele¹, Stacey L Ishkanian, Roberto Bogarin

¹Endocrinology and Diabetes Unit, British Columbia's Children's Hospital, University of British Columbia, 4480 Oak Street, Vancouver, Canada.

European Journal of Endocrinology

|July 8, 2008

Summary

Long-acting octreotide reduced ghrelin levels in adolescents with Prader-Willi syndrome but did not impact body mass or appetite. Further research should explore specific ghrelin inhibitors for PWS treatment.

More Related Videos

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

Related Experiment Videos

Last Updated: Jul 3, 2026

Roux-en-Y Gastric Bypass Operation in Rats

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

Area of Science:

Endocrinology
Metabolic Disorders
Pediatric Endocrinology

Background:

Ghrelin, a hormone primarily from the stomach, exists in acylated and desacyl forms, with acylated ghrelin stimulating appetite.
Elevated ghrelin concentrations in Prader-Willi syndrome (PWS) suggest its potential role in hyperphagia and obesity.
Adolescents with PWS often experience hyperphagia and overweight, necessitating effective therapeutic strategies.

Purpose of the Study:

To investigate the effect of long-acting octreotide on acylated and desacyl ghrelin concentrations in adolescents with PWS.
To evaluate the impact of octreotide on body mass, appetite, and compulsive eating behaviors in this population.
To assess the safety and tolerability of long-acting octreotide in treating PWS.

Main Methods:

A 56-week prospective, randomized, cross-over trial involving nine adolescents with PWS.
Participants received intramuscular injections of octreotide (30 mg) or saline every four weeks for 16 weeks, followed by a 24-week washout period.
Measurements included ghrelin concentrations, body mass index (BMI) Z-score, appetite, compulsive behavior, and biochemical markers.

Main Results:

Octreotide significantly decreased both acylated (-53%) and desacyl (-54%) fasting ghrelin concentrations (P<0.05).
No significant improvements were observed in BMI, appetite, or compulsive eating behaviors.
Octreotide led to decreased insulin-like growth factor-I, increased HbA1c, transient hyperglycemia in two subjects, and gallstone formation in three subjects.

Conclusions:

Long-acting octreotide effectively reduces ghrelin levels in adolescents with PWS but does not improve body mass or appetite.
Future interventions should focus on specific ghrelin secretion inhibitors or receptor antagonists.
Targeting ghrelin pathways requires careful consideration of effects on other appetite-regulating peptides.